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Abstract
Background: Breast cancer in women is increasingly frequent, and care is complex, onerous and
expensive, all of which lend urgency to improvements in care. Quality measurement is essential to
monitor effectiveness and to guide improvements in healthcare.
Methods: Ten databases, including Medline, were searched electronically to identify measures
assessing the quality of breast cancer care in women (diagnosis, treatment, followup,
documentation of care). Eligible studies measured adherence to standards of breast cancer care in
women diagnosed with, or in treatment for, any histological type of adenocarcinoma of the breast.
Reference lists of studies, review articles, web sites, and files of experts were searched manually.
Evidence appraisal entailed dual independent assessments of data (e.g., indicators used in quality
measurement). The extent of each quality indicator's scientific validation as a measure was
assessed. The American Society of Clinical Oncology (ASCO) was asked to contribute quality
measures under development.
Results: Sixty relevant reports identified 58 studies with 143 indicators assessing adherence to
quality breast cancer care. A paucity of validated indicators (n = 12), most of which assessed quality
of life, only permitted a qualitative data synthesis. Most quality indicators evaluated processes of
care.
Conclusion: While some studies revealed patterns of under-use of care, all adherence data
require confirmation using validated quality measures. ASCO's current development of a set of
quality measures relating to breast cancer care may hold the key to conducting definitive studies.
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Background
Cancer is the second-most common cause of death (after
cardio-vascular disease) in North Americans, and breast
cancer is the most commonly diagnosed cancer in women
[1]. It was estimated in 2004 that one in seven American
women would develop breast cancer in her lifetime [1],
up from one in eight estimated in 2003 [2].
During the 1990's, American women's 5-year breast can-
cer survival rates improved on average 2.3% per year, with
the largest improvements for younger women. However,
survival rates are generally lower for African American
women, with 30% excess deaths compared with white
women estimated in the year 2000 [3]. Thus, while some
aspects of breast cancer care (e.g., earlier detection) have
contributed to improved survival, increasing rates of dis-
ease and disparities in outcomes point to outstanding
issues to be addressed.
The enormous toll on women, families and society make
it urgent that breast cancer care be as effective, safe, acces-
sible and equitable as possible. The foundation of this
investigation must be sound research to refine what repre-
sents "quality care" (e.g., timely access to efficacious and
safe treatments). Only by measuring and monitoring
adherence to recommended care can meaningful trends
and gaps in the delivery, receipt and outcomes of care be
identified and put in context, at all levels, from individual
centers to nationally and globally [4].
Health care quality measurement is an emerging field,
developing alongside the establishment of goals for
health care delivery and utilization. Ideally, stakeholders
within the health care system will assess internal quality
improvement and accountability, and oversee external
health care quality, by appropriate measurement of the
rates of adherence to recommended care. This would
guide policy, the provision of care, and future research
directions.
The quality of health care is "the degree to which health-
care services ... increase the likelihood of desired health
outcomes and are consistent with current professional
knowledge" [5]. Despite more than a trillion dollars spent
annually on health care in general in the USA, however, it
is suggested that the care received by Americans falls well
short of ideal [6]. On average, almost half of those in need
do not receive recommended care [7,8].
Health care quality measurement may address a question
such as: How many women in a given clinical situation
(e.g., diagnosis, treatment history) receive a standard of
care (e.g., radiation following surgery) within a specific
time frame? Similar questions, yet ones which might yield
different results, could be: How many health care practi-
tioners offer or deliver a particular standard of care to
women in a specific clinical situation? Patient refusal of
care may account for discrepancies in rates identified by
these questions.
The assessment of the delivery or receipt of quality health
care may seem deceptively straightforward, with large
quantities of data available in health care records or can-
cer registries, for example. These data sources permit the
measurement of rates of adherence to recommended
health care processes (e.g., a competent and timely action
by the health care practitioner), structures (e.g., the availa-
bility of diagnostic imaging equipment), or outcomes (e.g.,
event-free survival; quality of life).
It is not sufficient simply to compile information from
health records, health care providers or patients related to
a definition of quality care (e.g., if diagnosis X, then
deliver care Y within Z weeks). Scientific validation is
needed to ensure that data specifically and repeatedly
reflect details defining the care in question; that measure-
ments accurately reflect patterns of practice. Indeed, with-
out ensuring scientific soundness, a definition given to
individuals extracting data from medical records, or used
to solicit information from other data sources (e.g.,
patients), may complicate or even prevent the identifica-
tion of what was intended. Unless health care indicators
survive the rigors of a scientific process and are found to
have sound psychometric properties, they cannot for-
mally be considered quality "measures" per se. In the
absence of validated measures, observations may be mis-
leading.
What, then, are the requirements for the development of
a sound quality measure?
The definition of quality care should be evidence-based
[7], possibly with a subsequent expert consensus process,
and with details that are precisely expressed (e.g., in a clin-
ical practice guideline). For example, quality care for
women with early stage breast cancer entails the receipt of
radiotherapy following breast-conserving surgery. Evi-
dence from randomized controlled trials (RCTs) has
shown that this less invasive, less disfiguring strategy
brings survival outcomes identical to those following
mastectomy. This definition of quality care is considered
an indicator of quality care, or quality indicator (e.g., if
early stage breast cancer in women, then radiotherapy fol-
lowing breast-conserving surgery within a specific time-
frame). Establishing the rate of adherence to this quality
(care) indicator according to a specific data source
amounts to quality measurement.
The definition of a quality indicator must be specific,
complete, and clearly worded regarding, for instance, theBMC Cancer 2006, 6:291 http://www.biomedcentral.com/1471-2407/6/291
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target population (e.g., women with specific diagnoses)
and the characteristics of the care (e.g., the order, type and
timing of care). It must be verified that different users
share the same meaning and therefore make the same
observations when, on different occasions, they consult
various data sources (e.g., clinic or hospital records) to
gather data. This verifies an indicator's reliability as a qual-
ity measure.
Additional scientific validation is necessary to increase the
confidence that the measured rate of adherence reflects
the actual delivery/receipt of particular care (e.g., "per-
centage of women receiving radiotherapy after breast-con-
serving surgery"). Along with reliability, sound validity
indicates and ensures that observations unambiguously
reflect what was intended to be identified. For example,
only data pertaining to the details circumscribed by the
quality indicator should be sought and collected (e.g., the
request to identify clinical outcome data should not result
in extraction of data for surrogate measures).
Project Scope
Our rationale in conducting this systematic review was to
identify extant quality measures, which could be
employed by stakeholders (e.g., service providers) to
assure or improve the quality of breast cancer care in
women. While it is our view that validated quality meas-
ures are required to appropriately ascertain the quality of
breast cancer care in women, both formally developed
quality measures, as well as quality indicators having
received little or no scientific development, were eligible
for inclusion in our review. It was thought that it would
add value to this project, but practical constraints made it
impossible to evaluate the soundness of the empirical evi-
dence supporting recommended standards for care.
Methods
A seven-member Technical Expert Panel (TEP) provided
advisory support, including refining the questions, high-
lighting key variables requiring consideration in the evi-
dence synthesis and supporting refinement of the scope of
the project. Detailed methods information, including the
search strategy and data assessment/abstraction forms is
available elsewhere [9].
Study Identification
Various electronic bibliographic databases (Medline, Can-
cerlit, Healthstar, Premedline, Embase, CINAHL,
Cochrane Database of Systematic Reviews, Database of
Abstracts of Reviews of Effectiveness, Cochrane Central
Register of Controlled Trials, and, Health and Psychoso-
cial Instruments (HAPI)) were searched for reports pub-
lished from 1992 to 2003 relevant to breast cancer
diagnosis and treatment, and quality measures. Another
search to retrieve systematic reviews of breast cancer treat-
ment or diagnosis was executed in Medline and Cancerlit,
with retrieval limited to material published after 1993.
Additional published or unpublished literature was
sought through manual searches of reference lists of
included studies and key review articles, and from the files
of content experts. Web sites were searched, including
AHRQ's National Quality Measures Clearinghouse. The
American Society of Clinical Oncologists (ASCO) was at
that time developing care quality measures, but wished
first to complete its work before disseminating it. After
removing duplicate citations via Reference Manager™
(Thomson ResearchSoft, Carlsbad, CA.), bibliographic
records were identified and posted to a secure internet-
based software system for review.
Following calibration exercises, bibliographic records
(level 1), and then retrieved articles (level 2) were
screened for relevance, with two reviewers per stage. A
final screening (level 3) excluded reports describing clini-
cal practice guidelines, systematic reviews, and commen-
taries/editorials that had initially passed into data
abstraction before the project scope was narrowed to
exclude examination of the strength of the empirical evi-
dence supporting any given recommended breast cancer
care. Disagreements were resolved by consensus and, if
necessary, third party intervention. Excluded studies were
noted as to the reason for their ineligibility using a modi-
fied QUOROM format [10].
Inclusion/Exclusion Criteria
The population of interest was female adults, diagnosed
with or in treatment for breast cancer, including all histo-
logical types of adenocarcinoma, both in situ and invasive.
Quality measurement efforts had to have focused on at
least one data source (e.g., medical records; cancer regis-
tries; patient or provider questionnaires), entailed any
sampling strategy (e.g., convenience sample over a period
of time in a health care setting; hospital medical records;
general population sample from a given region) and
could index any domain (e.g., structure; process).
Searches were restricted to post-1992 because, in the opin-
ion of the funders, quality measurement efforts concern-
ing breast cancer care began to receive serious attention in
the ten years prior to the initiation of this project.
Quality indicators could be derived from any source (e.g.,
clinical practice guideline) and have been subjected to any
degree of scientific development, but reference had to
have been made to the empirical evidence supporting
each indicator. A standard of care (e.g., a recommenda-
tion in a guideline) serving as the basis for quality meas-
urement had to have been established prior to the quality
measurement effort, so that it would have been available
at the time to guide the care subsequently assessed usingBMC Cancer 2006, 6:291 http://www.biomedcentral.com/1471-2407/6/291
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the quality indicator. Given the unique issues related to
breast cancer, measures of quality of life (QOL) and
patient satisfaction had to have been developed or
adapted for use with breast cancer patients. Inflammatory
breast cancer, Paget's disease, phyllodes tumors, and
benign breast conditions were excluded. A separate initia-
tive is addressing breast cancer screening and prevention.
Data Abstraction
Following a calibration exercise involving two studies,
three reviewers independently abstracted the contents of
each included study using an electronic data abstraction
form. Abstracted data were then verified by a second
reviewer. Data included: report characteristics (e.g., publi-
cation status); study characteristics (e.g., data sources);
population characteristics (e.g., case characteristics [size
of tumor; level of lymph node involvement; presence/
absence of metastasis]); characteristics of the quality indi-
cators used in quality assessment (e.g., data concerning
reliability, validity, and study-obtained links to outcomes;
whether data extractors were trained and extractions were
independently verified) [10]; and adherence data (e.g.,
overall adherence rate; variations in rates based on review-
relevant stratifications such as age; possible reasons for
failure to receive care, including patient refusal).
After a calibration exercise involving two included studies,
each quality indicator was assessed independently by two
reviewers to determine the extent of its scientific develop-
ment as a quality measure. Levels of development were:
I – quality indicator was developed prior to its implemen-
tation in the present study, according to scientific princi-
ples (e.g., assessment of scientific soundness, feasibility
and ease of use, reliability, internal validity, sensitivity,
and pilot testing with appropriate rigor and relevant data
sources);
II – quality indicator was being actively developed as part
of the present quality measurement study;
III – quality indicator was not currently under develop-
ment, but existing psychometric data were reported; or,
IV – quality indicator was not currently under develop-
ment and no psychometric data were reported. Levels I-III
could be further subdivided according to the soundness of
the reported psychometric properties.
Data Synthesis
Data from relevant studies were synthesized qualitatively,
including: diagnosis; treatment (including supportive
care); followup care; and the reporting/documentation of
care.
Variables to be taken into consideration included the
study population (e.g., age, race/ethnicity, socioeconomic
status), data sources (e.g., cancer registries), sampling
techniques (e.g., convenience sample, random general
population sample), and the purpose of the indicators/
measures (e.g., internal quality improvement). Other
parameters of interest included measurements of out-
comes linked to the quality measurements, and psycho-
metric properties of the identified quality measures (e.g.,
sensitivity and specificity for diagnostic tests).
Quantitative syntheses of adherence data were not possi-
ble, given the paucity of data from validated measures.
Results
Lists of included and excluded studies (with reasons for
exclusion), evidence and summary tables and a compre-
hensive report are available electronically elsewhere [9]
Results of record retrieval and screening are summarized
in Figure 1. From 3,848 unique records identified at the
outset, 60 reports, describing 58 studies, met eligibility
criteria, and 143 quality indicators were identified (Table
1).
Many different populations were investigated, typically
retrospectively, using various reference standards (e.g.,
clinical practice guidelines) and data sources (e.g., medi-
cal records). Younger women, and those with early stage
breast cancer, were more likely to have been studied. Most
standards reflected processes of care, focusing most often
on whether or not women with breast cancer received
indicated care (e.g., percentage of women treated with
breast-conserving surgery who begin radiation therapy
within 6 weeks of completing either of the following: the
last surgical procedure on the breast (including recon-
structive surgery that occurs within 6 weeks of primary
resection) or chemotherapy, if patient receives adjuvant
chemotherapy, unless wound complications prevent the
initiation of treatment; percentage of women having first
localization biopsy operation to correctly identify impal-
pable lesions). There were few investigations of the qual-
ity with which this care was delivered. The quality
indicators were employed to serve internal quality
improvement or external quality oversight.
Database choices reflected study rationale. Small, local
databases were used for internal quality improvement,
while large databases were used to assess and compare
adherence to care across various, larger jurisdictions. The
single study linking a quality measurement to outcome
noted that reporting the number of affected lymph nodes
was linked to both overall and disease-free survival [11].BMC Cancer 2006, 6:291 http://www.biomedcentral.com/1471-2407/6/291
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Modified QUOROM Flow Chart Figure 1
Modified QUOROM Flow Chart.
Potentially relevant citations identified and screened for possible retrieval (n = 3,848)
Citations excluded via screening of bibliographic records, with reasons (n = 2,937):
a.  not breast cancer in women (n = 928);
b.  not breast cancer diagnosis or treatment (or followup or reporting/documentation)
 (n = 1,137);
c.  not a quality measure/ment, clinical practice guideline, systematic review, or,
 commentary/editorial (n = 860); &,
d.  not a quality measure/ment (i.e., a clinical practice guideline, systematic review, or,
 commentary/editorial) (n = 12)*
Reports retrieved for more detailed assessment of relevance (n = 911)
Reports excluded via Level 2 relevance assessment, with reasons (n = 610):
a. not breast cancer in women (n = 52);
b. not breast cancer diagnosis or treatment (or followup or reporting/documentation)
(n = 40); &,
c. not a quality measure, clinical practice guideline, systematic review, or, commentary/
editorial (n = 518)
Other reports not proceeding, with reasons (n = 16):
a.  never retrieved (n = 4); &,
b.  retrieved too late to complete screening (n = 12)
Reports (n = 60) describing unique studies (n = 58) entered into qualitative
synthesis (i.e., 2 studies were each described by 2 reports)
Meta-analysis deemed inappropriate for each research question
*Due to narrowed scope of review.
Reports excluded via Level 3 relevance assessment, with reasons (n = 225)*
a. not a quality measure/ment (clinical practice guideline) (n = 94);
b. not a quality measure/ment (systematic review) (n = 115); &,
c. not a quality measure/ment (commentary/editorial) (n = 16)BMC Cancer 2006, 6:291 http://www.biomedcentral.com/1471-2407/6/291
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The only scientifically validated quality measures that
were identified assessed QOL (n = 11) and patient satis-
faction (n = 1) [12-22]. Of the 12 validated quality meas-
ures, 11 were used with reference to treatment and one
with regards to diagnosis. None pertained to followup or
the documentation of care. Two QOL scales had been spe-
cifically validated for use with breast cancer populations.
The Functional Assessment of Cancer Therapy Scale
(FACT-B, version 3) evaluated the QOL associated with a
diagnosis of breast cancer [16]. The European Organiza-
tion of Research and Treatment of Cancer (EORTC) QLQ-
BR23 scale [20] was employed to evaluate the impact of
treatment. Other validated instruments included: the
Patient Satisfaction Questionnaire [20], Short Form-36
[12,14,16,18,22], EORTC-C30 [14,15]., Medical Out-
comes Scale [16,17], Spitzer Quality of Life Index [21],
Uniscale [21], Ferrans Quality of Life scale [20], Psychoso-
cial Adjustment to Illness Scale [20], Guttman Health Sta-
tus Questionnaire [16], and the Linear Analogue Self-
Assessment Scale [15].
Overall, where gaps in care appeared to exist, they were
generally marked by patterns of under-use rather than
lower quality of delivered care. Reports of disparities in
breast cancer care amongst groups at risk of being disad-
vantaged (by age, race, socio-economic status, health
insurance) are summarized in Table 2. This includes
reports from a wide range of population mixes and sizes,
in differing settings, and employing varying standards of
optimal care. For example, definitions of "younger"
ranged from <40 years to <70 years. Most of the quality
indicators were defined in terms of whether or not the
indicated care had been received, rather than the quality
of the care. No group was advantaged regarding QOL, and
Table 1: Quality Indicators Used to Measure Adherence to Standards of Breast Cancer Care
Type of Quality Indicator n Extent of scientific development as a quality measure*
Diagnosis
Appropriate use of imaging, sampling (fine-needle or biopsy) within given time-frame 8 IV
Adequacy of fine-needle biopsy samples 1 IV
Receipt of frozen section of primary operable BC 1 IV
Quality of surgical technique, sampling nodes 2 IV
Quality of hormone receptor assay 1 IV
Quality of life and patient satisfaction relating to diagnosis 2 Iac
Appropriate referral to surgeon 2 IV
Appropriate (timely) attendance at assessment centre, specialist appointment, surgery, receipt of 
information by patient
5I V
Efficient diagnosis (few visits to hospital) 1 IV
Appropriate evaluation vis a vis guidelines, or at first visit 2 IV
Appropriate specialist knowledge of surgeons 1 IV
Treatment
Appropriate surgical choices – breast conserving, mastectomy, lymph node dissection 7 IV
Timely admission for therapeutic surgery 1 IV
< 3 operations for breast-conserving surgery 1 IV
Evidence of discussion of surgical options 1 IV
Appropriate use, timeliness of initial radiotherapy 6 IV
Quality of radiotherapy planning, fractionation, radiation field distribution 7 IV
Regional recurrence 1I V
Appropriate use of radiotherapy for regional recurrence, palliation 1 IV
Appropriate use (or not) of adjuvant systemic therapy 23 IV
Chemotherapy quality of administration – dosages and availability of procedure manual 2 IV
Quality of life, satisfaction with treatment 6 Ia, Iac
Participation in decision-making, receipt of sufficient information re. treatment 2 IV
Qualifications of doctors 2I V
Appropriate referrals to specialists 2 IV
Appropriate treatment choices, sequences 5 IV
Followup
Appropriate followup mammography, use of guidelines 2 IV
Recurrence within 5 years 2I V
Appropriate use of prophylactic radiotherapy in women with high risk of flap recurrence 1 IV
Reporting/Documentation
Pathology reporting/documentation 42 IV
Imaging reporting/documentation – size of mammographic abnormality 1 IV
Chemotherapy reporting/documentation 2 IV
n = number of different quality indicators regarding this type; *extent of scientific development of quality indicator: Level Ia = pre-study data 
indicating consistently sound psychometric properties; Iac = pre- and on-study data indicating consistently sound psychometric properties; IV = no 
pre- or on-study psychometric dataBMC Cancer 2006, 6:291 http://www.biomedcentral.com/1471-2407/6/291
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the satisfaction study indicated no advantage related to
age [17]. Satisfaction was higher among white women
and those with government insurance.
Twenty-six quality indicators were identified regarding
events surrounding diagnosis, with most not fitting into
the project's predefined categories. These measures
reflected recommendations that women be seen by spe-
cific types of health care professional, for specific reasons,
and within certain time frames. The greatest number of
studies evaluating a given quality indicator focused on a
recommendation pertaining to the use of preoperative
diagnosis by fine-needle aspiration cytology, needle
biopsy or biopsy (n = 4). Most quality indicators referred
to the delivery or receipt of indicated diagnostic care
(75%: 18/24). Only five addressed the quality with which
specific diagnostic care was delivered. One study observed
sound on-study reliability data for an instrument previ-
ously validated as a QOL measure [19]. Quality measure-
ments were not found relating to sentinel node biopsy,
chest X-ray, bone scan, CT scan, MRI, blood tests, tumor
marker status, or genetic testing.
Many more quality indicators were employed to assess
treatment (n = 67). The most frequently assessed treat-
ments were adjuvant systemic therapy (n = 25) and radia-
tion therapy (n = 16). The greatest number of studies
employing a given treatment-related quality indicator
evaluated the appropriate use of breast-conserving surgery
(n = 18), and the appropriate use of radiotherapy follow-
ing breast-conserving surgery (n = 19). Most of the quality
indicators referred to the delivery or receipt of indicated
treatment (70%: 47/67). Nine quality indicators assessed
the quality with which specific treatment care was deliv-
ered. Quality measurements were not found relating to
reconstructive surgery or neodjuvant systemic therapy,
nor to late-stage treatment and palliative care.
Followup care was the focus of five quality indicators,
none of which were validated. Specific types of followup
care were not predefined.
Of 45 quality indicators relating to reporting/documenta-
tion, pathology reporting was the most frequently
assessed (n = 42). Reporting the assessment of micro-
scopic margins, and reporting histological type (micro-
scopic) were each evaluated in five studies. Neither
surgical nor radiotherapy reporting were the focus of qual-
ity measurement.
Discussion
The measurement of the quality of breast cancer care is in
its infancy, despite the fact that breast cancer in women is
one of the most-studied areas of healthcare [23].
The clearest observations from this systematic review are
that most efforts to measure adherence to quality breast
cancer care have centered on whether or not appropriate
care was delivered or received (rather than on the quality
of this care), focused on treatment, and failed to employ
quality indicators formally developed as quality meas-
ures. As well, the quality indicators identified did not
cover many of the predefined types of diagnostic or treat-
ment care of interest to the funders.
Nearly all quality measurements entailed quality indica-
tors for which no reference was made, or data reported,
indicating that they had been developed scientifically as
quality measures. Only QOL and satisfaction with care
indicators had been validated. Thus, while many measure-
ments were identified, very few were conducted with vali-
dated quality measures. In the absence of sufficient data
yielded by the application of validated quality measures,
the decision was made to forego meta-analysis. For the
same reasons, adherence data need to be interpreted with
caution. Potential gaps in care compiled in Table 2 unfor-
tunately do not contribute substantially to understanding
the divergence of outcomes for American women of dif-
ferent ethnic origins for example.
Malin et al. reviewed breast cancer care literature post-
1985 [24], and although the present project had a later
commencement date, the same quality indicators of
breast cancer care were identified.
McGlynn  et al.'s efforts to establish clinically relevant,
valid quality indicators for breast cancer care [8] via a
review of the evidence and a peer consensus process, and
their findings of under-use, must be considered prelimi-
nary. Their study was based on a small number (n = 192)
of eligible breast cancer cases; the evidence supporting
some (especially treatment) standards was observational
by nature, or based on expert opinion; and the quality
indicators had not been pilot-tested as measures. Further-
more, patient preference could have been considered [25].
If patient refusal of treatment had been uniformly taken
into account, observations of "gaps" may have been dif-
ferent. Under-use of optimal treatment strategies by cer-
tain patient groups may arise for a multitude of cultural
reasons, and only if measures are sensitive to diverse
issues will health care for all citizens be improved. These
are some of the issues to be uncovered as part of the for-
mal development of measures.
The most important weakness of the present review is
that, due to practical constraints, the "strength" of the
clinical evidence base (i.e., the consistency of the results of
high quality, appropriately-designed, and adequately-
powered primary studies indicating significant links
between care and improved outcomes) supporting theB
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Table 2: Quality of Treatment of Breast Cancer in Women of Different Age, Socio-economic Status, Race or Ethnicity
Number of reports indicating the group is advantaged, according to measure
Measure Age Race Health Insurance Education Income Urban Rural
Young Old All Colored White All Private Government All High Low All High Low All
Pre-operative mammogram 1 1 1
Referral to surgeon by G.P. 1
Diagnostic evaluation per guidelines 1 1
Satisfaction with care 11 1
Appropriate breast-conserving surgery and axillary lymph node dissection 7 3 2 1 2 1 1
Appropriate radiotherapy 5 2
Appropriate systemic therapy 5 3 2 1 1 1 1
Appropriate treatment alternatives 3 11
Use/Quality of Radiotherapy 1 3 2 1
Improvement in QOL over time 1
Appropriate axillary lymph node dissection and chemotherapy 1BMC Cancer 2006, 6:291 http://www.biomedcentral.com/1471-2407/6/291
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definition of each quality indicator (i.e., standard of care)
could not be examined. A second limitation is likely that
the "level of scientific development" scheme designed
especially for this study was itself employed without the
benefit of a validation process. Nevertheless, most reports
did not describe any validation of their quality indicators,
so this limitation did not ultimately affect the results of
the review.
Considerable work remains, to define and to measure
adherence to standards of breast cancer care. While empir-
ical evidence will likely continue to be collected and syn-
thesized in the pursuit of defining quality breast cancer
care, the translation of quality indicators (even with
strong support from evidence and clinical consensus) into
quality measures with an equally strong psychometric
foundation is likely the most pressing need for this field
of inquiry to progress. However, before researchers rush
headlong into efforts to generate quality measures in the
scientific manner described above, it may be wise to
appraise the soundness of quality measures under devel-
opment by ASCO.
ASCO has been developing a set of quality measures relat-
ing to stages I-III breast cancer [26]. Their goal is to pro-
duce a robust set of largely evidence-based indicators that
were being pilot-tested using multiple data sources (e.g.,
patient survey, ACOS's National Cancer Database) and
published with a detailed profile of their reliability (e.g.,
inter-rater, inter-database), feasibility, and validity. It is
hoped that these will be the validated measures required
to push forward the field of quality measurement with
respect to breast cancer care. It remains to be seen whether
or not these quality measures will cover aspects of care
(e.g., quality of delivery of care, structural factors) and
components of care (e.g., reconstructive surgery, neoadju-
vant systemic therapy, sentinel node biopsy, chest X-ray,
bone scan, CT scan, MRI, blood tests, tumor marker sta-
tus, genetic testing, followup, and treatment of recurrent
disease and palliative care) identified by the present
review as being largely absent from the literature.
Future research efforts to measure adherence to quality
breast cancer care could be conducted prospectively, if
health care practices and systems were modified to accom-
modate the required data collection. Virtually all of the
efforts to date have involved retrospective data capture.
While this strategy reduces the waiting time for collection
of especially long-term (e.g., 5 year survival) outcomes,
retrospective data collection also makes it difficult to
ensure that some of the key factors potentially influencing
adherence-to-care data can be observed (e.g., reasons for
patient refusal of care).
Conclusion
A clear, comprehensive understanding of the quality of
breast cancer care received by the average citizen is neces-
sary before quality of healthcare may be seriously
addressed on a national level [27]. Reliable, validated
quality measures with which to identify confidently pos-
sible gaps in breast cancer care, and to afford accountabil-
ity, improvement, and research [28], are the first step to
resolving this issue. Some promise is attached to ASCO's
ongoing development of breast cancer quality measures,
although it will be some time before the results are
known. It may be best to proceed with caution before
allowing even minor decisions to be guided by any of the
adherence data reviewed in this report.
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